Cipla invests $90 million in API plants; Isis gets EMA nod for California plant;

> In its annual report, India-based Cipla says it will invest about $89.9 million to build active pharmaceutical ingredients (API) facilities at Patalganga, Mumbai, Bengaluru, Karnataka, and Kurkumbh, Pune, India. Annual report

> The Medicines and Healthcare Products Regulatory Agency in the U.K. has updated its 45-year-old regulations over drug manufacturing and distribution. Story

> An Isis Pharmaceuticals plant in Carlsbad, CA, has received EMA approval in anticipation of launch in Europe of Kynamro, a lipid-lowering drug it is developing with Genzyme. Story

> Materia has extended for another decade an agreement with Sigma-Aldrich for global distribution of its catalyst technology. Item

And Finally... Japanese regulators have approved for distribution in Japan Teijin's Bonalon Jelly, the first time the osteoporosis drug has been manufactured in this form, the company says. Release

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.